Eli Lilly Q4 earnings down 3.6%
Global pharmaceutical company Eli Lilly reported lower fourth-quarter earnings of 3.6% as the drug maker recorded weaker revenue as the sales of its antipsyschotic drug Zyprexa continued to drive lower revenue.
The results beat Wall Street expectations and the pharmaceutical company raised its forecast for 2013. The earnings per share on a non-GAAP basis, declined 2% to $0.85 from $0.87, yet topped market expectations of $0.78 a share.
The net earnings also dipped 2% to $945 million. Revenue also dipped 1% to $5.96 billion but came in better than Wall Street projections of a drop of 3.9%. In the U.S, total revenues also fell 2% and fell 1% outside the U.S.
Besides, Zyprexa revenue also dipped 49% while the revenue from depression treatment Cymbalta surged 20%. The gross margin as a percent of total revenue improved 0.9 percentage points to 79.0 percent for the fourth quarter. The volumes also dipped 3% due to the loss of patent exclusivity for Zyprexa in most major markets.
The cost of sales dropped 6% and operates expenses declined 1%. Eli Lilly currently expects non-GAAP EPS in the range of $3.82 to $3.97 versus $3.75 to $3.90 projected earlier. The revenue is still expected between $22.6 and $23.4 billion.
On a reported basis, Eli Lilly now forecasts EPS of $4.10 to $4.25, up from prior guidance of $4.03 to $4.18 projected earlier.
The increased outlook reflects the estimated benefit from the delayed enactment of the American Taxpayer Relief Act of 2012, the company said. Lilly said it expects the overall revenue growth for 2013, driven by products including Humalog, Humulin, Cialis, Forteo, Cymbalta, outside the U.S. and other products, including those in animal health.
Besides, it also expects significant revenue growth in Japan and the emerging markets, particularly in China. The company has already spent $400 million of the $1.5 billion stock buyback effort it unveiled last month.
Eli Lilly and Company is a global pharmaceutical company. Its global headquarters is located at Indianapolis, Indiana in the U.S. The company also has offices in Puerto Rico and 17 other countries.
Dexcom: changing the lives of people with type 1 diabetes
It is estimated that 9.3% of adults around the world are living with type 1 diabetes, which amounts to a total of 463 million people. A further 1.1 million children and adolescents under the age of 20 are living with the condition.
Unlike the more prevalent type 2 diabetes, where the body still produces insulin and symptoms develop slowly, people with type 1 diabetes need regular insulin injections or pumps, and must monitor their sugar levels frequently.
In recent years a number of remote glucose monitoring systems have become available that patients can use at home. These work with a sensor, usually placed under the skin, that measures glucose levels every few minutes. This information is then transmitted wirelessly to a device like a smartphone or tablet, which can then be shared with their clinician.
British actress Nina Wadia's son Aidan, 14, has type 1 diabetes, and has been managing his condition using Dexcom, a glucose monitoring system used by patients all over the world. Here Wadia explains how Dexcom has improved their lives.
As a parent of someone with type 1 diabetes, what is your day-to-day life like?
Being able to take a breath, think and pivot constantly without getting frustrated becomes an essential mindset because sometimes it feels like each day is determined to be different from the day before. Whatever worked yesterday is going to misfire today.
Which areas of yours and Aidan’s life are most impacted by diabetes?
The one thing that you have to fight hard to reclaim is spontaneity, especially when it comes to food and exercise. It’s only when this is taken do you realise how essential each one is. You can be flexible and there are no real limits, but only in the sense that a great athlete can be flexible without limits because they’ve trained super hard to be that way. So we’ve all had to become athletes when it comes to being spontaneous.
How has Dexcom helped you and Aidan?
Dexcom has brought future science fiction to real life today. The continuous glucose monitoring system is tiny, sits discreetly on his body and gives him a ten-day breather between sensor changes, so it's goodbye finger-pricking seven times daily.
Dexcom is totally active at a grass roots level and for Diabetes Awareness has pledged to donate £2,000 if #DexcomDiabetesStories and/or #DexcomWarriorStories is shared 200 times! I’ll be sharing more on social media and would love to hear how other families are winning their fights.
Maybe most importantly Dexcom is trying to introduce a reimbursement programme for type 1 diabetes patients which will give greater access to modern, life changing hi-tech. I want to spread the word on the importance of accessing it through this campaign.
If you compared your life today with how it was before Aidan was using Dexcom, what has changed?
It's always working, which lets him take his mind off diabetes for longer stretches. It also lets me get off his back. We both receive alerts so I no longer have to pester him by asking him what his number is, and especially importantly, I don’t have to wake him at night to prick his finger if I’m worried. Dexcom gave us back our sleep!